Delcath Systems Value Stock - Dividend - Research Selection
Fundamental data and company key figures of the share
|Annual reports in
|Net operating cash flow
|Free cash flow
|Liabilities & Shareholders equity
|Diluted shares outstanding
✓ NEW Fundamental API Access to 500 data points per month
✓ Fundamental data up to 25 years
✓ Comparison to all other stocks by the FScore
✓ Time saving!
How our site works ...
✓ Non-binding 7 days without automatic subscription
✓ No termination required after the free week
✓ Finanzoo fundamental analysis
✓ Data updated daily
✓ Virtual depots
✓ Share alarms via email
✓ Subscription can be canceled at any time at the end of the month
✓ Choice of desired shares
✓ Over 2000 stock analyzes available
✓ Bitcoin payment possible if you do not want to subscribe
Price for monthly subscription $ 19.99 / month including VAT.
|Raw Data Source
Description of the company
Delcath Systems, Inc. (Delcath) is a pharmaceutical and medical device company specializing in oncology that focuses on developing medicines and initially causes cancer in the liver. Delcath focuses on the development and clinical study of the Delcath chemosuppressive system. The Delcath chemosaturation system allows the administration of concentrated regional chemotherapy by isolating the circulatory system of the target organ. Once the organ is isolated, the Delcath chemosuppression system delivers doses of chemotherapeutic agents directly to the liver. The Delcath chemosuppression system includes a series of three catheter insertions, each of which is placed percutaneously by interventional radiology techniques. The procedure is minimally invasive and repeatable, allowing for multiple treatment cycles with chemotherapeutic drugs. On April 13, 2011, it received the Conformite Europeenne (CE) mark for the Delcath Hepatic CHEMOSAT Delivery System (CHEMOSAT System).